TX-FLUENCE
21.9.2022 15:11:14 CEST | Business Wire | Press release
Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, has been selected by Wageningen University & Research (WUR) as the LED technology partner for its new Netherlands Plant Eco-phenotyping Centre (NPEC). In NPEC’s state-of-the-art phenotyping greenhouse, VYPR DUO 3x2 fixtures are used to support research on genotype-phenotype associations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220921005421/en/
In NPEC’s state-of-the-art phenotyping greenhouse, VYPR DUO 3x2 fixtures are used to support research on genotype-phenotype associations. (Photo: Business Wire)
The official opening of NPEC will take place preceding the weeklong International Plant Phenotyping Symposium 2022 (IPPS 2022), held from Sept. 26 to Sept. 30 in Wageningen, Netherlands. Fluence, a Gold Sponsor of IPPS 2022, will attend the conference and opening of NPEC in Wageningen.
NPEC consists of six modules across two university campuses, each offering dedicated phenotyping platforms with its own measurement systems. A specialized greenhouse at the WUR campus houses five climate-controlled compartments outfitted with Fluence’s VYPR DUO 3x2 fixtures. The compartments’ 3D and hyperspectral imaging, conveyor systems and various sensors produce high-precision measurements—including plant size, color and leaf positioning—that can be examined to understand the genetic response of plants to varied conditions and treatments, such as heat, drought or increased soil salinification.
“Using highly customizable technologies that generate high-quality plant performance data on how environmental parameters affect the plant phenotype was a key requirement when selecting our equipment partners,” said Rick van de Zedde, senior scientist and project manager for NPEC. “Having worked with Fluence for the lighting in our Serre Red high-tech quarantine greenhouse, we knew PhysioSpec™️ BROAD R4 white spectrum fixtures could help establish a near-ideal research environment in the NPEC greenhouse.”
In addition to Fluence’s VYPR top lights, which feature PhysioSpec™️ BROAD R4 white spectrum, NPEC researchers will use the Maxi-MARVIN imaging cabinet to assist in research, a high-throughput 3D modeling system developed by WUR that can reconstruct a plant’s architecture within milliseconds. Other high-tech research tools at WUR include a dark and light adaptation chamber and imaging systems capability to analyze the photosynthetic efficiency of plants.
“Establishing research on genotype-phenotype associations, specifically how ecological and environmental variables impact the plant phenotype, is essential for the development of novel, climate-proof crops,” explained van de Zedde. “Automated phenotyping will also allow for a dramatic increase in the speed of plant breeding and time to market for novel crop varieties.”
“We are honored to partner with WUR to advance the future of high-quality food production and sustainability in cultivation,” said Theo Tekstra, Fluence’s technical director for Europe, the Middle East and Africa and team lead for the WUR project. “Our PhysioSpec™️ BROAD R4 white spectrum came closest to what the WUR scientific team defined as an ideal spectrum to do year-round research on a wide range of plant species.”
Fluence's continuing partnership with WUR also includes LED fixtures in a specialized greenhouse for insect research and phenotyping climate rooms at Wageningen. Read more about Fluence’s collaborations with WUR here.
For more information on Fluence, visit www.fluence.science.
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220921005421/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom